| Literature DB >> 8016873 |
K H Böker1, B Ringe, M Krüger, R Pichlmayr, M P Manns.
Abstract
New concepts for the treatment of hepatitis B in immunocompromised patients are urgently needed. We describe our first experience with the new antiviral agent famciclovir in combination with a short course of prostaglandin E in a patient with severe hepatitis B after liver transplantation. Initial treatment with prostaglandin E reduced the inflammatory activity, as measured by transaminase activities, but did not affect viral replication. Consecutive long-term treatment with famciclovir further normalized liver function and profoundly suppressed viral replication. HBeAg and HBV-DNA -PCR all became negative and only HBsAg persisted. Histology documented marked reduction of cellular infiltration. The patient completely recovered and is back to regular work as a teacher.Entities:
Mesh:
Substances:
Year: 1994 PMID: 8016873
Source DB: PubMed Journal: Transplantation ISSN: 0041-1337 Impact factor: 4.939